By Elric Langton | 17th February 2022
SkinBioTherapeutics plc (AIM: SBTX), a life science business focused on skin health, has today provided a business update, including an update on the commercialisation progress of AxisBiotix-Psβ’.
Guess what? As it usually does, the share price falls because there seem to be quite a few investors struggling to join the dots. The same occurred when the company announced groundbreaking news on its performance of the antiaging lysate, and again, with the announcement of Croda Plc, the shares fell. Furthermore, it beggars belief, but we must accept this as part of the underbelly of the unsophisticated market on AIM.
The company was not generating any cash to Β£1.2 million by June, and some peeps sell! You are bonkers!!
A couple of crucial takeaways appear not to have registered with the investors selling today. First, I accept some may well be pleased with the recent rise off the low 30s - not too shabby, thanks to the first wave; us and then Tom Winnifrith.